Dear Brian
can you kindly clarify: if the kappa and lambda staining is absent, on what
basis do you consider this population 'clonal?' assuming these results are
obtained from bone marrow, has there been therapy since july?
regards
F Preffer
At 11:56 AM 01/07/2000 -0600, Newsom, Brian S. wrote:
>We have a pediatric male patient that presented in July of 1999 with
>neutropenia and a flow phenotype of 12% small (by FSC) cells positive for
>CD10,CD19,CD22, HLA-DRand 50% CD20, K and L negative. He is back in the
>clinic now with the exact same clonal population, still 12% and still the
>same phenotype. I have two questions about this?
>
>1. Everyone says that hematagones are CD22 negative. Is it possible that
>these are hematagones even though they are strongly CD22 positive?
>
>2. Are there any additional flow markers that we could use to help define
>these cells and diagnose the patient?
>
>Any help very much appreciated.
>
>Thanks,
>Brian Newsom
>Director, Flow Cytometry
>Center for Cell and Gene Therapy
>Baylor College of Medicine
>
>Attachment Converted: "C:\neweud\attach\Clinical case"
>
`````````````````````````````````````````````````
Frederic I. Preffer
preffer@helix.mgh.harvard.edu
Department of Pathology- Room 7140
149 13th Street
Massachusetts General Hospital-East
Charlestown, MA 02129
v(617) 726-7481 fax (617) 724-3164
~~~~~~~~~~~~~~~~~~~~~~~~~~~
This archive was generated by hypermail 2b29 : Sat Mar 10 2001 - 19:31:02 EST